# Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration

> **NCT00696592** · PHASE2 · WITHDRAWN · sponsor: **University of Padova**

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** Bevacizumab (Avastin), Verteporfin (Visudyne)

## Key facts

- **NCT ID:** NCT00696592
- **Lead sponsor:** University of Padova
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-01-31
- **Primary completion:** 2008-01-31
- **Final completion:** 2008-01-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** new data from clinical trials
- **Last updated:** 2025-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00696592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00696592, "Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00696592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*